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I. Introduction
The unsustainable growth in U.S. health care costs is
in large part attributable to the rising costs of pharmaceuticals and medical devices and to unnecessary
medical procedures.1 This fact has led health reform
advocates and policymakers to place considerable
hope in the idea that increased government support for
research on the comparative effectiveness of medical
treatments will eventually help to reduce health care
expenses by informing patients, health care providers, and payers about which treatments for common
conditions are effective and which are not.2 Comparative effectiveness research (CER) has shown in some
cases that expensive but commonly used treatments
are significantly less effective than relatively inexpensive alternatives.3 Critics warn, however, that CER will
homogenize patient care, limit patient choices, and
lead to improper health care rationing and even to the
denial of lifesaving treatments.4
In 2009, Congress allocated $1.1 billion in funding for CER, as part of the American Reinvestment
and Recovery Act (ARRA).5 The Patient Protection
and Affordable Care Act of 2010 (PPACA) embraced
CER as an important health care reform initiative and
established the Patient-Centered Outcomes Research
Institute to oversee CER in the United States.6 CER
represents a major public health enterprise, since
public health, broadly defined, includes all “federal,
state, and local governmental efforts to maintain and
protect the health of the general population.”7
This article explores a novel application of CER
that could enable physicians to make better treatment
decisions for patients by invoking electronic queries
of a large electronic health record (EHR) database.
The query responses would summarize the outcomes
of available treatments administered to patients with
similar clinical characteristics.
We propose the development of a broadly accessible
framework to enable physicians to rapidly perform,
through a computerized service, medically sound personalized comparisons of the effectiveness of possible
treatments for patients’ conditions. A personalized
comparison of treatment effectiveness (PCTE) for a
given patient (the subject patient) would be based on
data from EHRs of a cohort of patients who are similar to the subject patient (clinically, demographically,
genetically), who received the treatments previously
and whose outcomes were recorded. The proposed
framework would permit the patient’s physician to
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order a computerized, retrospective study based on
EHRs from the patient’s cohort within a large and
representative database of deidentified EHRs. Experts
would establish the parameters, outcome measures,
methodology, and technical infrastructure for all
PCTEs. The infrastructure would support PCTEs for
various conditions.

extent to which physicians’ freedom of action should
be limited by such evidence.10 However, in many cases
little is known about the comparative effectiveness of
different treatments for a given medical condition. In
the case of pharmaceuticals and medical devices in the
U.S., one reason for this is that the FDA approval processes generally do not require the effectiveness of a

This article explores a novel application of CER that could enable
physicians to make better treatment decisions for patients by invoking
electronic queries of a large electronic health record database.
The query responses would summarize the outcomes of available treatments
administered to patients with similar clinical characteristics.
The PCTE service could make a novel and valuable contribution to medical practice. PCTEs would
focus on identifying, for a given patient, an appropriate reference group (cohort) of similar, previously
treated patients whose EHRs would be analyzed to
choose the optimal treatment for the patient at issue.
This approach contrasts with the use of general clinical prediction models8 that are intended to capture
in a single mathematical construct the relationships
among treatment choices, clinical and other predictor variables, and prognoses for a large and diverse
population of patients. PCTEs may employ statistical
models, but these models would be fitted using data
from the cohort of previously treated patients who are
(or were) similar to the subject patient in clinically relevant ways. Basing treatment effect estimates on such
cohorts will enhance their predictive value. Using a
PCTE service, doctors could submit a wide range of
narrowly-tailored, treatment-effectiveness queries
from their desktop computers.
PCTEs have unique potential to simultaneously
improve the quality of health care, reduce its cost, and
alleviate public concerns about rationing and “one size
fits all” medicine.9 Therefore, they could serve as an
important tool in promoting the goals of the health
care reform initiative and make a significant contribution to public health.

II. PCTE Building Blocks: Comparative
Effectiveness Research and Electronic
Health Record Systems
A. Comparative Effectiveness Research
Many physicians agree that medical decisions should,
where possible, be based on a foundation of scientific
evidence, although there is disagreement about the
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new product to be compared to that of existing ones; it
is often sufficient for the manufacturer to provide evidence of the product’s safety and efficacy as compared
to a placebo.11 According to Alexander and Stafford,
 he FDA’s historical focus on common harms and
T
on evaluating efficacy against placebo has led to
testing in small, highly selected populations with
limited comorbidities. In turn, these studies have
failed to provide information most relevant to the
clinical contexts in which FDA-approved drugs or
devices are ultimately used.12
In 2009, the Institute of Medicine (IOM) recognized
the need for expanded CER and proposed initial
national priorities for it.13 The IOM report noted that
randomized controlled trials (RCTs) are the “gold standard” for determining treatment effectiveness because
they minimize bias in determining which patients
receive treatment and which serve as controls. However, it recognized that RCTs cannot answer many
comparative effectiveness questions and that observational data, such as that in EHRs, can help fill gaps
in evidence when RCTs are not possible or are inadequate. Some commentators have posited that retrospective analysis of EHR data should play an important role in bridging the “inferential gap” between “the
paucity of what is proved to be effective for selected
groups of patients versus the infinitely complex clinical decisions required for individual patients.”14
PPACA enthusiastically embraced CER as a major
health care reform initiative. The Act defines CER as
“research evaluating and comparing health outcomes
and the clinical effectiveness, risks, and benefits of 2
or more medical treatments, services, and items….”15
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CER is to be conducted through a wide variety of
means, including clinical trials, observational studies, and any other appropriate methodologies.16 The
goal of CER is to generate improved patient outcomes
while maximizing the value derived from health care
expenditures.17 PPACA emphasizes the importance of
developing evidence concerning “variations in patient
subpopulations” and of disseminating research findings so that they can be used by those making health
care decisions.18
Many commentators have expressed concern about
the challenges of applying CER findings to achieve
health care delivery improvements.19 CER would be of
little worth if its results were not operationalized in
the clinical setting. This article’s proposed PCTE tool
offers a novel, creative mechanism to move CER discoveries from bench to bedside so that it can be utilized effectively by health care providers and patients.
PCTEs would fit well within the CER goals articulated
in PPACA.
B. Electronic Health Records
An essential resource for CER generally and PCTEs
in particular are electronic health records (EHR).
The U.S. government has undertaken a major initiative to computerize all Americans’ health records by
2014. To that end, President Obama’s stimulus legislation, ARRA, dedicated $27 billion to the promotion
of health information technology. Under ARRA, clinicians may obtain payments of up to $44,000 from
the Medicare incentive program and $63,750 per clinician from the Medicaid program.20 In the years to
come, EHR systems will transform medical practice
in the United States. One of their many contributions
is likely to be providing health care professionals with
unprecedented research capabilities.
Health information technology advocates contemplate the development of a National Health Information Network (NHIN) of interoperable health information systems so that necessary exchanges of health
data can occur expeditiously. One of the potential benefits of the NHIN is that it could greatly facilitate CER
by providing medical researchers with access to what
is in effect a massive database of deidentified EHRs.21
This database could provide data that is invaluable for
assessing the benefits and risks of different medical
treatments in actual use.
The importance of large electronic databases for
research purposes is well recognized. A 2009 PricewaterhouseCoopers report22 called for public-private collaboration and a limited government role in
enabling the private sector to collect, share, and use
health data for secondary purposes, including CER.
The Veterans Health Administration already uses its

well-established EHR system to conduct extensive
assessments of performance and outcomes and to
operate an Evidence Synthesis Program.23 Likewise,
the Food and Drug Administration (FDA) is planning
to implement a national electronic system called the
Sentinel Initiative that will enhance the FDA’s ability
to monitor the safety of the products it regulates after
they reach the marketplace. The FDA hopes to be able
to send electronic queries to participating data holders such as health care providers and insurers, and
obtain summary responses from them.24 Broad proposals have also been entertained in the academic and
health policy literature. For example, Lynn Etheredge
recommended the establishment of both a National
Database for Effectiveness Research Studies and a
national network of new research registries and linked
databases to “capture key data from millions of patient
records so that comparative studies can cover all conditions, treatments, and patient groups.”25
C. Will CER Necessarily Lead to Better Health Care?
There is no guarantee that CER studies will automatically result in improved health outcomes. In the words
of one commentator, “having better information is
comparable to arriving at the base camp at Mount
Everest. Clinicians, patients, managers, and policy
makers need to work together to apply the results of
comparative research appropriately and consistently
if we are to reach the summit of reliable, evidencebased, and patient-centered care.”26 Collecting data
through research studies may be far easier than determining how they can be put to good use in the clinical
setting.
Another concern is that CER will yield results that
are not sufficiently individualized and that do not take
into account all of the factors that make particular
patients different from others. Thus, if doctors wrongly
assume that certain CER findings are generalizable
to all patients and base treatment decisions on these
research results, they may make erroneous decisions
in specific cases. Over-reliance on CER could lead
doctors to ignore lifestyle, genetic, medical history, or
patient preference factors that make a particular recommended therapy inappropriate for the individual
in question.27
It is not surprising that treatment guidelines
derived from estimates of average treatment effects for
a diverse population can lead to suboptimal or even
harmful results if they are applied naively to atypical
subpopulations or individuals. This fact is illustrated
by a 2009 retrospective study of the initiation of anticoagulation therapy with the drug warfarin in 5,052
patients.28 The investigators found that a pharmacogenetic algorithm for estimating the appropriate ini-
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tial dose of warfarin, which considered both clinical
and genetic factors, outperformed a standard dose of
35 mg per week (and also outperformed an algorithm
that considered only clinical factors), principally
because the pharmacogenetic algorithm’s estimated
doses were more efficacious (and presumably safer)
for “outliers” — patients who required 21 mg of warfarin or less per week or who required 49 mg or more
per week. In an accompanying editorial, Woodcock
and Lesko concluded that a “better understanding of
individual differences in the response, either positive
or negative, to medicines should be an overarching
goal for pharmacotherapy over the next decade. Pharmacogenetics has the potential to increase benefit and
reduce harm in people whose drug responses are not
‘average.’”29
CER is most controversial when it is discussed in
the context of cost effectiveness analysis (CEA) of different treatments.30 Proponents of CEA, such as the
American College of Physicians, see it as one valuable
tool (among others) for informing those responsible
for making decisions about medical expenditures.31
Critics, however, warn that CEA will lead to homogenized medicine, in which the treatment that is most
cost effective on average for a particular condition will
be given to all patients with the condition, even if it is
inappropriate for them.
Some warn that a primary focus of CER will in
fact be cost control. This could lead to care rationing and denial if specific treatments are perceived as
insufficiently cost effective or individuals are deemed
unlikely to experience sufficient enhancements of lifequality or longevity. PPACA aims to provide the public with reassurance in this regard, stating explicitly
that “[t]he Secretary shall not use evidence or findings
from comparative clinical effectiveness research…in
determining coverage, reimbursement, or incentive
programs…in a manner that treats extending the life
of an elderly, disabled, or terminally ill individual as
of lower value than extending the life of an individual
who is younger, nondisabled, or not terminally ill.”32
The best way to realize the potential benefits of CER
in the face of legitimate public concerns is to foster a
rational and appropriate demand for its results, based
on individual physicians’ and patients’ perceptions
of their own best interests. PCTEs constitute a CER
approach that could well serve this goal.

III. Personalized Comparisons of Treatment
Effectiveness
A. Overview
PCTEs would enable a patient’s physician to rapidly
perform, through a computerized service, a medically
sound personalized comparison of the effectiveness of
428

possible treatments for the patient’s condition(s), the
results of which would be provided, in readily comprehensible forms, to both the physician and the patient
(or guardian). This personalized comparison would be
based on the EHRs of a cohort of other patients with
the same condition who are similar to the given patient
in other ways that are relevant clinically, demographically, and perhaps genetically.
In technical terms, the proposed framework would
permit the patient’s physician to order a computerized, retrospective study based on EHRs from the
patient’s cohort within a very large and representative database of deidentified EHRs. The results from
this study would be adjusted statistically to take into
account potential biases, confounding variables, and
the results of well-regarded prior studies of the treatments in question, especially randomized controlled
trials. Admittedly, for some patients, no valid comparison would be possible, e.g., because no suitable cohort
could be identified in the EHR database. Before PCTEs
could be conducted on behalf of patients with a particular condition, experts would establish the parameters, outcome measures, methodology, and technical
infrastructure for them, as described in Part D.
Thus, for example, a doctor who wishes to use a
PCTE to help determine what treatment is best for a
particular patient with hyperthyroidism would access
an Internet service supporting PCTEs for hyperthyroidism patients. The physician would upload from
his or her patient’s EHR the values of relevant clinical
and demographic variables required for the PCTE. The
PCTE service would then mine the database to identify
EHRs of patients with similar values for those variables
who were treated previously for hyperthyroidism. The
records of patients who received particular treatment
options would be sorted into corresponding treatment
groups from which well-matched comparison groups
would be selected, if possible. The treatment outcomes
that were experienced by patients in the comparison
groups (as characterized by an approved set of outcome measures) would then be compared statistically.
Finally, the PCTE service would present to the physician and patient, in understandable ways, results that
accurately characterize the relative effectiveness of the
treatments for the patient’s cohort. The entire process
would be automated.
PCTE service providers would typically be commercial enterprises that would profit from use of
PCTEs. Health care providers could pay per query or
be charged monthly rates for unlimited use of the service. PCTE service providers should be motivated by
the prospect of economic gain to provide high quality
products and maximize user satisfaction.
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The use of a computerized tool to facilitate individual treatment decisions has precedents. For example,
Adjuvant! Online allows a doctor and cancer patient
to input information about the patient and receive
assistance in deciding upon the best course of treatment after surgery.33 Adjuvant! Online uses comparative effectiveness research that has already been
conducted to provide a treatment recommendation.
Under our proposal, the PCTE service would conduct
a comparative effectiveness analysis even if no formal
CER study had been completed.
Each PCTE would be based on a cohort of clinically
similar patients rather than on a general model or a
set of clinical practice guidelines. Thus, PCTEs would
be uniquely well-suited to simultaneously improve the
quality of health care, reduce its cost, and alleviate
public concerns about rationing and “one size fits all”
medicine.
There are numerous hurdles to successfully implementing and operating the proposed framework for
PCTEs, including technical, social, educational, economic, ethical, legal, and political ones. Our proposal
requires integrating cutting-edge developments in
medicine, health information technology, computer
science, and statistics. However, success is quite feasible, and the potential long-term benefits, in terms of
improved health, alleviated suffering, reduced health
care costs, and reduced health disparities easily justify
the investment required.
B. PCTEs and Personalized Medicine
Personalized comparisons of treatment effectiveness,
as proposed here, constitute a form of personalized
medicine. Personalized medicine can be defined as “the
delivery of health care in a manner that is informed
by each person’s unique clinical information; genetic,
genomic, and other molecular/biological characteristics; and environmental influences.”34
PCTEs would be consistent with this approach
because they would be based on relevant patient
variables whose values are recorded in EHRs, such
as variables representing demographic information,
clinical measures, aspects of medical or family history,
and known risk factors, possibly including genetic or
genomic factors.35 We use the term “covariates” to refer
to the set of variables used in a PCTE that do not represent medical treatments or outcomes and whose values were acquired before any outcome measures were
obtained. Ideally, the covariates, treatment variables,
and outcome variables would capture, in suitable
form, all of the information about individual patients
that is necessary to accurately estimate effect differences for treatments of a given condition. There may
be several, or even dozens, of covariates that are rel-

evant to a particular PCTE. We will also use the term
“profile” to mean a complete, ordered set of covariates
characterizing a patient. Different covariates will of
course be appropriate for different conditions.
In a PCTE, a very large EHR database is searched
to find a cohort for a patient needing treatment. Intuitively, this is the set of patients represented in the
database who were treated for the same condition,
who had similar profiles at the time they were treated,
and whose treatment outcomes were recorded. Given
an appropriate metric for measuring profile similarity
or dissimilarity,36 the cohort of a patient Jane Doe may
be defined as all patients whose profiles are within a
numeric similarity threshold T of Jane’s profile. The
threshold T should be chosen based upon a statistical
analysis of the distribution of profiles and treatments
for patients treated for Jane’s illness. The cohort should
be reasonably large and relatively homogeneous in
terms of covariate values. It should also be possible
to select suitable treatment comparison groups from
the cohort, each consisting of patients who received
a given treatment. These groups should be approximately balanced with respect to both size and covariate distribution. A number of techniques have been
developed for constructing such matched groups.37 A
personalized assessment of the relative effectiveness
of two treatments can be obtained, for example, by
estimating the average difference in treatment effects
between matched individuals in the corresponding
comparison groups.38
Note that PCTEs will be precluded for some patients
because suitable comparison groups cannot be found
(e.g., because the patients have unusual characteristics). Several techniques exist to detect lack of balance
among comparison groups.39 If multiple outcome measures exist for a condition, a PCTE may indicate that
one treatment is best with respect to one measure and
that another treatment is best by another measure. In
this case the patient’s physician would help him or her
interpret the results and decide on a course of action.
PCTEs should be used to compare only established
treatments or treatments that have been found to be
safe and efficacious based on RCTs.
C. PCTEs and Observational Studies
Personalized comparisons of treatment effectiveness
would rapidly provide doctors with actionable results,
based on computerized observational studies. Observational evidence has been recognized by commentators as an important component of CER.40 Observational studies allow investigators to examine very large
bodies of data based on treatments that were given to
diverse populations of patients in real world clinical
settings.
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Critics may object, however, to making treatment
decisions based on nonrandomized studies. The main
limitation of observational studies, and the main reason that randomized trials are preferred for estimating treatment effects, is that since treatment selection
(selection of patients to receive a particular treatment,
or to serve as controls) is not explicitly randomized in
an observational study, it may be influenced by confounding variables in ways that can seriously bias estimated treatment effects. For example, suppose that
doctors choosing between available treatments A and
B for a particular serious condition tend to order treatment A for younger, healthier patients and treatment
B for older, sicker patients, because of concern about
side effects of A in the latter individuals. If the estimated benefit of treatment A over the entire patient
population is greater than that of treatment B, then
this may be due to the prior conditions of the patients
who received the treatments and not to the superiority
of treatment A. Doctors may not even be aware of their
own subtle treatment biases, e.g., ones resulting from
having treated a particular mix of patients in the past.
Random treatment assignment, as in clinical trials,
helps to avoid such biases by tending to yield comparison groups that are approximately balanced in terms
of possible confounding factors. Even in clinical trials,
however, the groups might not be representative of
the overall population of patients with the condition
because of bias in the recruitment of subjects, loss of
subjects, and other factors.
Many physicians may be unaware that there has
been substantial progress in redressing the limitations of observational studies for clinical research
and for causal inference generally. This progress has
been spurred by a confluence of ideas and results
from such diverse fields as epidemiology, economics, social science, statistics, and computer science.41
The computer scientist Judea Pearl has presented a
conceptual framework and a methodology for causal
inference42 which unifies the major lines of causal
inference research and which provides a foundation
for conducting PCTEs. A key part of Pearl’s methodology is formulating causal assumptions using ordinary
scientific language and representing their structural
aspects in graphical form. The result is called a causal
model.
Even with state-of-the-art causal inference techniques, there is reason to doubt whether treatment
selection bias due to doctors’ and patients’ highly subjective judgments about prognoses, frailty, pain, and
other factors, made on the basis of information that is
not completely captured in patients’ EHRs, can be adequately controlled for based on standard EHR data.43
In order to address this issue, EHRs intended for use
430

in PCTEs could include physicians’ and patients’ own
ratings of hard-to-measure factors like level of frailty
or pain, e.g., on a numerical scale of one to ten.44 These
ratings would require normalization through appropriate statistical adjustments to account for rater tendencies, such as a consistent propensity to provide
high scores. In any case, the computerized service that
conducts a PCTE should subject the results to a procedure called quantitative bias analysis before reporting
it to the physician and patient.45 This analysis would
aim to detect any evidence that the results were seriously confounded by unknown variables, in which
case the problem would be reported to the patient’s
physician.
D. PCTE Oversight Committees
To be widely accepted, PCTEs must be subject to rigorous processes for their design, approval, and longterm monitoring. In light of space constraints, not
every aspect of these processes can be detailed in this
article, but a general operational framework is outlined below.
We envision that a commercial venture seeking to
provide PCTE services for a particular disease would
approach a leading professional organization for specialists in that area and request the formation of one
or more PCTE Oversight Committees (POC) to oversee the design and implementation of its PCTE services. Thus, a company wishing to focus on a type of
cancer could turn to the American Society of Clinical
Oncologists; one interested in cardiology PCTEs could
approach the American College of Cardiology; and a
PCTE service provider for diabetes could work with the
American Association of Clinical Endocrinologists.
Pursuant to a negotiated contract, the PCTE service
provider would pay the professional association a sum
of money that would be used to support each POC.
The association would then recruit POC members and
pay them an annual honorarium for their work. POCs
should consist of knowledgeable researchers, clinicians, statisticians, and patient advocates. In order to
limit the amount of work each POC must do, a professional organization might create several POCs, each
of which is tasked with addressing a subset of disease
problems.
For each kind of PCTE, the POC and PCTE service
provider, working together, should specify a causal
model that represents the known or suspected causal
relationships among treatments, covariates, outcome
measures, and other factors that could influence treatment results.46 Patient input should be obtained concerning what outcome measures are most important to
them. For example, these may involve not only disease
cures, but also pain, recovery time, impact on personal
journal of law, medicine & ethics
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appearance, complication rates, and side effects. The
POC and the PCTE service provider should also specify
the techniques to be employed to measure similarity
between patients and to identify cohorts. They should
ensure that the EHR database to be used is adequately
representative, and agree on a sound plan for validating the PCTE model and its implementation. The POC
should oversee the implementation and evaluation of
the PCTE service, approving or rejecting the results.
Large health care providers such as the Cleveland
Clinic or Kaiser Permanente might wish to implement
an internal PCTE service using their own patients’
EHRs. Such providers would not need to partner with
a professional organization, but rather, could use their
own experts. Nevertheless, they too would be required
to utilize a POC that meets regulatory requirements,
as described below.

used by their physician and should not suffer because
some commercial ventures are forced to obtain data
from second-rate sources. Moreover, because of the
limited number of leading medical professional organizations, exclusive contracts could preclude competitors from entering the market and thus violate antitrust law.47
Use of professional associations should optimize the
value of PCTEs and minimize the likelihood of conflicts of interest. If commercial PCTE service providers
were to hire experts directly to formulate PCTEs, they
might pressure such independent contractors to produce a large volume of work quickly, to the detriment
of quality, in order to launch the service as soon as
possible. Unlike commercial enterprises, professional
associations would not be motivated by the prospect
of large profits, because they would be limited to the

Unlike commercial enterprises, professional associations would not be
motivated by the prospect of large profits, because they would be limited
to the specified contractual payment. In addition, professional organizations
should have the interest of their members as their top priority, and therefore,
they will wish to ensure that PCTEs are as helpful as possible to physicians
and minimize medical malpractice exposure. To that end, the organizations
should ensure that all POC members have appropriate and current
expertise and are free of conflict of interest.
In other instances, business enterprises might wish
to compete with existing PCTE service providers and
to offer a different PCTE service, just as Google competes with other search engine providers. Professional
associations should be free to contract with and provide POC services to multiple commercial ventures.
Associations should not have to establish entirely new
POCs for different commercial ventures. POCs should
be able to share the same causal model for a given
condition and the same criteria for identifying cohorts
with any commercial PCTE service providers, and the
POC should inform all providers of refinements to the
model or criteria. A POC would not, however, share
a PCTE service provider’s proprietary design details
with other service providers, and legal safeguards
would have to be implemented to protect intellectual
property rights and trade secrets. Sharing the same
well-researched causal model and cohort identification criteria with all PCTE service providers that are
focusing on a particular condition would safeguard
the consistency and quality of PCTE results. Patient
outcomes should not depend upon the PCTE service

specified contractual payment. In addition, professional organizations should have the interest of their
members as their top priority, and therefore, they will
wish to ensure that PCTEs are as helpful as possible to
physicians and minimize medical malpractice exposure. To that end, the organizations should ensure that
all POC members have appropriate and current expertise and are free of conflict of interest.
Professional associations already have experience
in formulating guidelines for clinicians. The National
Guideline Clearinghouse lists over 2,500 clinical
practice guidelines, many of which are published by
associations.48
Because POCs would consist of individuals who
chose to serve on the committees, their members can
be expected to be dedicated to the work. The fact that
POC members will be paid by the association should
increase their accountability and sense of responsibility. For the sake of clarity, contracts between professional associations and PCTE service providers should
specify conditions under which a contract will be
deemed to have been breached (e.g., if a POC is not
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formed by the association within a specified period of
time or a particular phase of the project is not completed by a deadline).
Much as research institutions maintain ongoing
Institutional Review Boards (IRBs), professional
associations would need to maintain POCs on a longterm basis. Long-term monitoring of PCTE services
would be necessary to ensure that results remain
trustworthy in light of emerging research and input
from physicians and patients who use the service.
POCs should conduct continuing reviews, periodically
surveying member physicians concerning their PCTE
experiences as well as periodically auditing a sample
of recent PCTEs and investigating the health status
of the patients for whom they were conducted.49 In
addition, physicians and patients who use the service
should be able to report concerns about it to the relevant POC, with the assurance that concerns will be
considered carefully.
Government oversight over both POCs and PCTE
service providers would be essential to ensure the safety
and efficacy of PCTE services. Just as federal regulations govern the composition of IRBs,50 the Department of Health and Human Services (HHS) should
formulate regulations concerning POC membership,
requiring that they include qualified researchers, clinicians, and community members who are patient
advocates. The responsibilities of POCs should also be
specified in regulations.
PCTE service providers must be required by regulation to utilize an appropriate POC to determine PCTE
covariates and a causal model and to avoid conflicts of
interest because of which commercial profit might be
prioritized over patient care. In addition, HHS should
be authorized to mandate periodic reports from
PCTE service providers and to investigate suspected
problems.
E. Technical Infrastructure
Conducting PCTEs on a large scale requires designing
and implementing a technically complex PCTE query
service. Such a service would require a distributed software system that would, when invoked by a physician
in order to conduct a PCTE for a patient, retrieve (or
prompt for) the data about the patient that is required
by the PCTE’s causal model, mine the EHR database
to identify a suitable cohort, execute causal inference
procedures needed to characterize the relative effectiveness of the treatments under consideration, and
characterize statistical uncertainty about the results.
The service’s user interface would be critically important. It must guide the physician so he or she does
not make mistakes that would invalidate the PCTE.
It must also help the physician to properly interpret
432

the results and warn of any limitations of the analysis.
In essence, the user interface must serve the role of
the physician’s own clinical research consultant. The
entire PCTE service should be developed with adherence to the best practices for software engineering,
health informatics, and information security, and it
should be required to undergo rigorous pre- and postdeployment evaluation.51
The most realistic approach to developing a comprehensive PCTE service is to do so incrementally,52
beginning with medical conditions that are both common and especially well suited to PCTEs. If the initial
offerings were successful, the number of PCTE types
available to physicians would be likely to grow over the
years, as new PCTE service providers enter the market
and as more POCs are formed to oversee the establishment of PCTEs for additional conditions.
Fortunately, it is not necessary to establish a nationwide network of interoperable EHR systems, such
as the proposed NHIN, or a comprehensive solution to the problem of representing medical concepts
unambiguously in concrete data structures53 before
implementing PCTEs. The most important requirements for the EHR database to be queried are that its
records be representative of the actual patient population and that it be large enough to enable suitable
cohorts to be identified for most patients. If a patient’s
relevant characteristics are unusual, only a very large
EHR database is likely to contain a sufficient number
of records of patients with similar characteristics to
enable valid statistical inferences to be made about
treatment effects.
The required EHR database could be created from
the EHRs of one large health care system or those
of multiple health care providers who agree to share
their EHR data and to adopt common data standards.
A major health system such as the Cleveland Clinic or
Mayo Clinic is likely to have a sufficiently large and
diverse patient population to permit using its own
EHR system as a database for conducting PCTEs, and
health care networks will be motivated to implement
such a service if it is shown to improve outcomes and
to add to their profits. On the other hand, relatively
small and resource-poor institutions that wish to
conduct PCTEs will not be able to rely on their own
EHRs alone. Instead, they will have to either participate in a federated system54 that searches the EHRs
of multiple organizations or employ a PCTE service
provided by a larger organization.
Carol Diamond and her coauthors note that, in the
context of public health, a federated system obviates
the need for different organizations to share their data
about individuals and thereby eliminates a number of
attendant problems, including privacy risks.55 Organijournal of law, medicine & ethics
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zations participating in a federated system can share
group-level summary data, such as means and proportions, which are computed locally.
A federated system would not be unprecedented.
DARTNet is an existing federated network that consists of electronic health data from eight organizations representing more than 500 clinicians and over
400,000 patients, which was created to facilitate
observational CER about prescription medications
and medical devices.56 DARTNet does not allow a full
set of patient data to leave individual clinical sites;
however, it permits queries that return deidentified
data about individuals.
To reduce privacy risks, a federated system for conducting PCTEs could, at each participating organization, identify a local “sub-cohort” (subset of a cohort)
for a subject patient, based on the latter’s deidentified
profile, but return to the PCTE service only summary
statistics about the sub-cohort and possibly a fitted
statistical model (e.g., a regression model) characterizing the relationships between treatments, covariates,
and outcome(s) for the sub-cohort. The PCTE service
would combine the data characterizing each subcohort (e.g., using multilevel modeling techniques)57
to produce final predictions of treatment effects for
the subject patient. The participating organizations
would each need to support a common communication protocol and common set of statistical operations,
but they would not have to provide one another with
data about individual patients even in deidentified
form.
F. Data Quality
Two of the greatest challenges to realizing the potential benefits of PCTEs are the quality and completeness of the data contained in EHRs.58 Amanda Terry
et al. list five characteristics of EHR data that affect
their use in research:
( i) providers decide where to put information
(uniqueness of use); (ii) information may be
entered in free-text form instead of being entered
in defined fields or picked from a structured list of
medical terms; (iii) providers use different terms
for the same information (lack of standardization); (iv) information may not be stored in a way
that is readily searchable and (v) data that are not
important to clinical care [but are important for
research] may be missing.59
The authors identify two issues as central to data quality: (1) the need to code all presenting comorbidities
and (2) developing criteria for identifying patients
who have the specific condition to be studied.

A particularly noteworthy difficulty is that in
some cases, treatment outcomes are not reported. A
patient who receives medication and whose condition
improves may not require follow-up and is unlikely to
contact the doctor to report her satisfaction with the
course of therapy. A lack of further patient visits may
suggest treatment success, but it may also indicate
that the patient is economically disadvantaged and
does not have regular access to health care providers.
An absence of definitive data in this regard could be
problematic for PCTE purposes.60
Increasing use of electronic means for collecting
patient data, such as remote patient monitoring,61 has
the potential to mitigate problems with the completeness and accuracy of EHR data. Furthermore, health
care organizations that wish to offer PCTEs may be
willing to create strong incentives for internal compliance with standards for patient follow-up and data
entry, because they view data quality as essential to
their goals.
Ultimately, the federal regulations suggested above
may need to address data integrity. It would be advisable for regulators to establish and enforce national
standards for interoperability and data quality.62
G. Evaluation of PCTE Services
It will also be important to conduct clinical trials to
evaluate the safety and efficacy of particular PCTE
services. To illustrate, a clinical trial could include
breast cancer patients who are randomly assigned to
two arms: one in which physicians use PCTEs and
one in which they do not. Investigators must recognize that the results of such studies will be somewhat
obfuscated by the fact that physicians will be at liberty
to disregard PCTEs in light of their own judgment or
patients’ rejection of the recommended treatment.
Therefore, researchers would need to evaluate not
only the ultimate outcomes of patients in both study
arms, but also the actual recommendations that the
PCTEs made and physicians’ reasons for ignoring any
of them.
PCTE services should facilitate reporting by physicians and HIT personnel of adverse events related to
their use, such as serious usability problems or failures
that lead to improper recommendations. This could be
accomplished by incorporating a well-designed problem-reporting mechanism into the service, which could
be invoked simply by clicking an icon. The occurrence
of adverse events should promptly be shared with the
POC and appropriate federal authorities for assessment.
H. The Risks and Benefits of PCTEs
PCTEs are likely to raise concerns about privacy.
Despite deidentification of records, many patients
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may worry about confidentiality and the ability of
third parties to trace sensitive information to them.63
Consequently, careful attention should be paid to
ensuring the integrity of the deidentification process
and the security of EHR databases. 64 In addition,
questions may be raised concerning whether patients
have a property right in their health information 65
and to what extent they should be asked to consent
to their records’ use in PCTEs. For example, should
patients have an opportunity to opt out of inclusion
in the PCTE enterprise altogether? Should they be
allowed to limit use of their deidentified records, such
as by refusing to have them included in PCTEs relating to reproductive services? Would complying with
such patient preferences be administratively feasible?
These matters warrant further consideration.
PCTE service providers would also have to be trusted
to maintain patient confidentiality. When processing
PCTE queries, they would receive sensitive information concerning patients and their medical conditions.
Although patients would not be identified by name to
the service provider, patients might become identifiable through various demographic details and the
name of their treating physicians.66 Patients may worry
that PCTE service providers will furnish search information to health insurers, who in turn might refuse
to pay for treatments in instances in which a physician deviated from PCTE recommendations. Potential
disclosures to other third parties, such as employers,
financial institutions, and marketers would also be of
concern.67
PCTE service providers who have contracts with
hospitals or health networks are likely to be considered business associates by the HIPAA Privacy Rule
and to be bound by its confidentiality mandates.68
However, PCTE service providers with a pay per query
arrangement rather than contracts may not be covered
entities. Consequently, the HIPAA Privacy Rule would
need to be amended to state explicitly that PCTE service providers fall within its scope.
Another obstacle to adoption of PCTEs may be physicians’ attitude toward them. Some physicians may
object to giving a computerized service significant
influence in treatment decisions, and some may even
feel threatened by PCTEs. Physicians may also feel
that they cannot afford the time required to initiate
PCTEs and interpret the results. These concerns can
be alleviated by a combination of skillful design of the
service, strong evidence for the benefits of PCTEs, and
appropriate incentives for using them implemented
by physicians’ employers, hospitals, and others.
It is also possible that PCTEs will exacerbate health
disparities because not all patients will be able to pay
for their use. If patients must pay out of pocket for
434

PCTE queries, then only those with sufficient financial resources will be able to pay for the service. However, if PCTE use is shown to be cost effective because
it improves outcomes and, when appropriate, leads
clinicians to opt for less expensive treatments than
they may have otherwise selected, then private and
public insurers may well choose to cover the cost of
the service.
There is good reason to hope that PCTEs will help
lower health care costs by addressing the imbalance of information that often exists between buyers
and sellers of health services.69 Ideally, the results of
PCTEs would lead physicians and patients to choose
treatments that better control symptoms and cure
diseases, thus reducing the need for further medical
care.
Patients who must absorb a significant portion of
the cost of care because of high deductibles or copayments may also appreciate accurate information
that allows them to make cost-effective decisions. For
example, they may choose to forego a very expensive
treatment and opt for a relatively inexpensive one that
is only marginally less effective overall.
Physicians would utilize PCTE services only when
they believe doing so would be beneficial, and we
would not support institutional policies that require
doctors and patients to follow PCTE recommendations. Doctors should maintain their professional discretion and patients their autonomy. PCTE services
are meant to be only one tool in the medical toolbox,
but they have the potential to be a very valuable asset
for health care providers and to facilitate optimal
treatment decisions.

IV. Conclusion
This article proposes the development of a national
framework to allow physicians to conduct electronic
comparisons of treatment effectiveness (PCTEs) that
are personalized with respect to individual patients’
clinically relevant characteristics. Each comparison would be based on the electronic health records
of a cohort of clinically similar patients. Substantial
groundwork must be laid before PCTEs can be made
widely available. Given that EHR systems are not yet
in general use,70 adequate EHR data about individuals’
long-term treatment effects is likely to be unavailable
for some time. However, with proper design and oversight, PCTEs hold great promise to empower patients
and physicians, reduce medical costs, and significantly
improve public health.
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